Braveheart Bio (NASDAQ:BRVE) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Braveheart Bio (NASDAQ:BRVE) in a research report report published on Monday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $40.00 price objective on the stock.

A number of other analysts have also commented on BRVE. The Goldman Sachs Group assumed coverage on shares of Braveheart Bio in a research note on Monday. They set a “buy” rating and a $48.00 price objective for the company. Wall Street Zen raised shares of Braveheart Bio to a “hold” rating in a research report on Saturday, August 15th. Jefferies Financial Group began coverage on shares of Braveheart Bio in a report on Monday. They set a “buy” rating and a $48.00 price target on the stock. Finally, TD Cowen started coverage on shares of Braveheart Bio in a research report on Monday. They issued a “buy” rating for the company. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $45.25.

Braveheart Bio Stock Up 2.5%

NASDAQ:BRVE opened at $26.95 on Monday. Braveheart Bio has a 1-year low of $24.31 and a 1-year high of $32.00.

Insider Buying and Selling at Braveheart Bio

In other Braveheart Bio news, Director Orbimed Advisors Llc purchased 1,940,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the transaction, the director owned 11,901,826 shares of the company’s stock, valued at approximately $214,232,868. This represents a 19.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Erez Chimovits acquired 1,940,000 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the purchase, the director owned 11,901,826 shares in the company, valued at approximately $214,232,868. This represents a 19.47% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 8,751,942 shares of company stock valued at $157,534,956 in the last ninety days.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.